Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

FGF-23 and secondary hyperparathyroidism in chronic kidney disease.

Silver J, Naveh-Many T.

Nat Rev Nephrol. 2013 Nov;9(11):641-9. doi: 10.1038/nrneph.2013.147. Epub 2013 Jul 23. Review.

PMID:
23877588
2.

Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.

Koizumi M, Komaba H, Fukagawa M.

Contrib Nephrol. 2013;180:110-23. doi: 10.1159/000346791. Epub 2013 May 3. Review.

PMID:
23652554
3.

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M.

J Am Soc Nephrol. 2005 Jul;16(7):2205-15. Epub 2005 May 25.

4.

Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.

Hu P, Xuan Q, Hu B, Lu L, Wang J, Qin YH.

Int J Biol Sci. 2012;8(5):663-71. doi: 10.7150/ijbs.3886. Epub 2012 May 5. Review.

5.

The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.

Diniz H, Frazão JM.

Nefrologia. 2013 Nov 13;33(6):835-44. doi: 10.3265/Nefrologia.pre2013.Jul.12091. Epub 2013 Oct 25. Review.

6.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

7.

FGF-23 in children with CKD: a new player in the development of CKD-mineral and bone disorder.

Siomou E, Stefanidis CJ.

Nephrol Dial Transplant. 2012 Dec;27(12):4259-62. doi: 10.1093/ndt/gfs315. Epub 2012 Jul 29.

PMID:
22848110
8.

[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].

Komaba H.

Clin Calcium. 2010 Jul;20(7):1028-36. doi: CliCa100710281036. Review. Japanese.

PMID:
20585181
9.

Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1268-76. doi: 10.2215/CJN.08241109. Epub 2010 May 6.

11.

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M.

Am J Kidney Dis. 2004 Aug;44(2):250-6.

PMID:
15264182
12.

Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.

Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M.

J Am Soc Nephrol. 2008 Mar;19(3):615-23. doi: 10.1681/ASN.2007060673. Epub 2008 Jan 23. Erratum in: J Am Soc Nephrol. 2009 Jan;20(1):229.

13.

Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.

Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M.

Am J Kidney Dis. 2004 Sep;44(3):481-7.

PMID:
15332221
14.

Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.

Muras K, Masajtis-Zagajewska A, Nowicki M.

J Clin Endocrinol Metab. 2013 Dec;98(12):E1901-8. doi: 10.1210/jc.2013-2418. Epub 2013 Oct 3.

PMID:
24092829
15.

Clinical relevance of FGF-23 in chronic kidney disease.

Seiler S, Heine GH, Fliser D.

Kidney Int Suppl. 2009 Dec;(114):S34-42. doi: 10.1038/ki.2009.405. Review.

PMID:
19946326
16.

Role of Klotho in aging, phosphate metabolism, and CKD.

John GB, Cheng CY, Kuro-o M.

Am J Kidney Dis. 2011 Jul;58(1):127-34. doi: 10.1053/j.ajkd.2010.12.027. Epub 2011 Apr 15. Review.

17.

Dietary interventions for mineral and bone disorder in people with chronic kidney disease.

Liu Z, Su G, Guo X, Wu Y, Liu X, Zou C, Zhang L, Yang Q, Xu Y, Ma W.

Cochrane Database Syst Rev. 2015 Sep 16;(9):CD010350. doi: 10.1002/14651858.CD010350.pub2. Review.

PMID:
26376110
18.

[Clinical aspect of recent progress in phosphate metabolism. Pathophysiology of secondary hyperparathyroidism in chronic kidney disease].

Goto S, Fukagawa M.

Clin Calcium. 2009 Jun;19(6):809-14. doi: CliCa0906809814. Review. Japanese.

PMID:
19483275
19.

Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.

Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1021-30. doi: 10.2215/CJN.03270314. Epub 2015 Apr 14.

20.

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M.

Kidney Int. 2011 Jun;79(12):1370-8. doi: 10.1038/ki.2011.47. Epub 2011 Mar 9. Erratum in: Kidney Int. 2012 Aug;82(4):498.

Supplemental Content

Support Center